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Abstract
Background: The assessment of calibration performance of risk prediction models based on regression or more
flexible machine learning algorithms receives little attention.
Main text: Herein, we argue that this needs to change immediately because poorly calibrated algorithms can be
misleading and potentially harmful for clinical decision-making. We summarize how to avoid poor calibration at
algorithm development and how to assess calibration at algorithm validation, emphasizing balance between model
complexity and the available sample size. At external validation, calibration curves require sufficiently large samples.
Algorithm updating should be considered for appropriate support of clinical practice.
Conclusion: Efforts are required to avoid poor calibration when developing prediction models, to evaluate
calibration when validating models, and to update models when indicated. The ultimate aim is to optimize the
utility of predictive analytics for shared decision-making and patient counseling.
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Background
Medical predictive analytics have gained popularity
in recent years, with numerous publications focusing
on models that estimate patients’ risk of a disease or
a future health state (the ‘event’) based on classical
regression algorithms or modern flexible machine
learning or artificial intelligence algorithms [1–3].
These predictions may support clinical decision-
making and better inform patients. Algorithms (or
risk prediction models) should give higher risk esti-
mates for patients with the event than for patients
without the event (‘discrimination’). Typically, dis-
crimination is quantified using the area under the
receiver operating characteristic curve (AUROC or
AUC), also known as the concordance statistic or c-
statistic. Additionally, it may be desirable to present
classification performance at one or more risk
thresholds such as sensitivity, specificity, and
(stratum-specific) likelihood ratios. Herein, we focus
on calibration, another key aspect of performance
that is often overlooked. We define calibration, de-
scribe why it is important, outline causes for poor
calibration, and summarize how calibration can be
assessed.
Main text
Discrimination is important, but are the risk estimates
reliable?
It is often overlooked that estimated risks can be
unreliable even when the algorithms have good dis-
crimination. For example, risk estimates may be sys-
tematically too high for all patients irrespective of
whether they experienced the event or not. The ac-
curacy of risk estimates, relating to the agreement
between the estimated and observed number of
events, is called ‘calibration’ [4]. Systematic reviews
have found that calibration is assessed far less often
than discrimination [2, 3, 5–7], which is problematic
since poor calibration can make predictions mislead-
ing [8]. Previous work has highlighted that the use
of different types of algorithms, varying from regres-
sion to flexible machine learning approaches, can
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lead to models that suffer greatly from poor calibra-
tion [9, 10]. Calibration has therefore been labeled
the ‘Achilles heel’ of predictive analytics [11].
Reporting on calibration performance is recom-
mended by the TRIPOD (Transparent Reporting of
a multivariable prediction model for Individual
Prognosis Or Diagnosis) guidelines for prediction
modeling studies [12]. Calibration is especially im-
portant when the aim is to support decision-making,
even when discrimination is moderate such as for
breast cancer prediction models [13]. We explain
the relevance of calibration in this paper and sug-
gest solutions to prevent or correct poor calibration
and thus make predictive algorithms more clinically
relevant.
How can inaccurate risk predictions be misleading?
If the algorithm is used to inform patients, poorly cal-
ibrated risk estimates lead to false expectations with
patients and healthcare professionals. Patients may
make personal decisions in anticipation of an event,
or the absence thereof, that were in fact misguided.
Take, for example, a prediction model that predicts
the chance that in vitro fertilization (IVF) treatment
leads to a live birth [14]. Irrespective of how well the
models can discriminate between treatments that end
in live birth versus those that do not, it is clear that
strong over- or underestimation of the chance of a
live birth makes the algorithms clinically unaccept-
able. For instance, a strong overestimation of the
chance of live birth after IVF would give false hope
to couples going through an already stressful and
emotional experience. Treating a couple who, in real-
ity, has a favorable prognosis exposes the woman un-
necessarily to possible harmful side effects, e.g.,
ovarian hyperstimulation syndrome.
In fact, poor calibration may make an algorithm less
clinically useful than a competitor algorithm that has
a lower AUC but is well calibrated [8]. As an ex-
ample, consider the QRISK2–2011 and NICE Fra-
mingham models to predict the 10-year risk of
cardiovascular disease. An external validation study of
these models in 2 million patients from the United
Kingdom indicated that QRISK2–2011 was well cali-
brated and had an AUC of 0.771, whereas NICE Fra-
mingham was overestimating risk, with an AUC of
0.776 [15]. When using the traditional risk threshold
of 20% to identify high-risk patients for intervention,
QRISK2–2011 would select 110 per 1000 men aged
between 35 and 74 years. On the other hand, NICE
Framingham would select almost twice as many (206
per 1000 men) because a predicted risk of 20% based
on this model actually corresponded to a lower event
rate. This example illustrates that overestimation of
risk leads to overtreatment. Conversely, underestima-
tion leads to undertreatment.
Why may an algorithm give poorly calibrated risk
predictions?
Many possible sources may distort the calibration of
risk predictions. A first set of causes relates to vari-
ables and characteristics unrelated to algorithm de-
velopment. Often, patient characteristics and disease
incidence or prevalence rates vary greatly between
health centers, regions, and countries [16]. When an
algorithm is developed in a setting with a high dis-
ease incidence, it may systematically give overesti-
mated risk estimates when used in a setting where
the incidence is lower [17]. For example, university
hospitals may treat more patients with the event of
interest than regional hospitals; such heterogeneity
between settings can affect risk estimates and their
calibration [18]. The predictors in the algorithm
may explain a part of the heterogeneity, but often
differences between predictors will not explain all
differences between settings [19]. Patient popula-
tions also tend to change over time, e.g., due to
changes in referral patterns, healthcare policy, or
treatment policies [20, 21]. For example, in the last
10 years, there has been a drive in Europe to lower
the number of embryos transferred in IVF and im-
provements in IVF cryopreservation technology led
to an increase in embryo freezing and storage for
subsequent transfer [22]; such evolutions may
change the calibration of algorithms that predict
IVF success [23].
A second set of causes relates to methodological prob-
lems regarding the algorithm itself. Statistical overfitting is
common. It is caused by a modeling strategy that is too
complex for the amount of data at hand (e.g., too many
candidate predictors, predictor selection based on statis-
tical significance, use of a very flexible algorithm such as a
neural network) [24]. Overfitted predictions capture too
much random noise in the development data. Thus, when
validated on new data, an overfitted algorithm is expected
to show lower discrimination performance and predicted
risks that are too extreme – patients at high risk of the
event tend to get overestimated risk predictions, whereas
patients at low risk of the event tend to get underesti-
mated risk predictions. Apart from statistical overfitting,
medical data usually contain measurement error, for ex-
ample, biomarker expressions vary with assay kits and
ultrasound measurement of tumor vascularity has inter-
and intra-observer variability [25, 26]. If measurement
error systematically differs between settings (e.g., measure-
ments of a predictor are systemically more biased upward
in a different setting), this affects the predicted risks and
thus calibration of an algorithm [27].
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How to assess calibration?
The concepts explained in this section are illustrated in
Additional file 1, with the validation of the Risk of Ovar-
ian Malignancy Algorithm (ROMA) for the diagnosis of
ovarian malignancy in women with an ovarian tumor
selected for surgical removal [28]; further details can be
found elsewhere [1, 4, 29].
According to four increasingly stringent levels of cali-
bration, models can be calibrated in the mean, weak,
moderate, or strong sense [4]. First, to assess ‘mean
Fig. 1 Illustrations of different types of miscalibration. Illustrations are based on an outcome with a 25% event rate and a model with an area
under the ROC curve (AUC or c-statistic) of 0.71. Calibration intercept and slope are indicated for each illustrative curve. a General over- or
underestimation of predicted risks. b Predicted risks that are too extreme or not extreme enough
Van Calster et al. BMC Medicine          (2019) 17:230 Page 3 of 7
calibration’ (or ‘calibration-in-the-large’), the average
predicted risk is compared with the overall event rate.
When the average predicted risk is higher than the over-
all event rate, the algorithm overestimates risk in gen-
eral. Conversely, underestimation occurs when the
observed event rate is higher than the average predicted
risk.
Second, ‘weak calibration’ means that, on average,
the model does not over- or underestimate risk and
does not give overly extreme (too close to 0 and 1)
or modest (too close to disease prevalence or inci-
dence) risk estimates. Weak calibration can be
assessed by the calibration intercept and calibration
slope. The calibration slope evaluates the spread of
the estimated risks and has a target value of 1. A
slope < 1 suggests that estimated risks are too ex-
treme, i.e., too high for patients who are at high risk
and too low for patients who are at low risk. A
slope > 1 suggests the opposite, i.e., that risk esti-
mates are too moderate. The calibration intercept,
which is an assessment of calibration-in-the-large,
has a target value of 0; negative values suggest over-
estimation, whereas positive values suggest
underestimation.
Third, moderate calibration implies that estimated
risks correspond to observed proportions, e.g., among
patients with an estimated risk of 10%, 10 in 100
have or develop the event. This is assessed with a
flexible calibration curve to show the relation between
the estimated risk (on the x-axis) and the observed
proportion of events (y-axis), for example, using loess
or spline functions. A curve close to the diagonal in-
dicates that predicted risks correspond well to ob-
served proportions. We show a few theoretical curves
in Fig. 1a,b, each of which corresponds to different
calibration intercepts and slopes. Note that a calibra-
tion intercept close to 0 and a calibration slope close
to 1 do not guarantee that the flexible calibration
curve is close to the diagonal (see Additional file 1
for an example). To obtain a precise calibration curve,
a sufficiently large sample size is required; a mini-
mum of 200 patients with and 200 patients without
the event has been suggested [4], although further re-
search is needed to investigate how factors such as
disease prevalence or incidence affect the required
sample size [12]. In small datasets, it is defendable to
evaluate only weak calibration by calculating the cali-
bration intercept and slope.
Fourth, strong calibration means that the predicted
risk corresponds to the observed proportion for every
possible combination of predictor values; this implies
that calibration is perfect and is a utopic goal [4].
The commonly used Hosmer–Lemeshow test is
often presented as a calibration test, though it has
many drawbacks – it is based on artificially group-
ing patients into risk strata, gives a P value that is
uninformative with respect to the type and extent of
miscalibration, and suffers from low statistical
power [1, 4]. Therefore, we recommend against
using the Hosmer–Lemeshow test to assess
calibration.
How to prevent or correct poor calibration?
When developing a predictive algorithm, the first
step involves the control of statistical overfitting. It
is important to prespecify the modeling strategy and
to ensure that sample size is sufficient for the num-
ber of considered predictors [30, 31]. In smaller
datasets, procedures that aim to prevent overfitting
should be considered, e.g., using penalized regres-
sion techniques such as Ridge or Lasso regression
[32] or using simpler models. Simpler models can
refer to fewer predictors, omitting nonlinear or
interaction terms, or using a less flexible algorithm
(e.g., logistic regression instead of random forests or
a priori limiting the number of hidden neurons in a
neural network). However, using models that are
too simple can backfire (Additional file 1), and pen-
alization does not offer a miracle solution for uncer-
tainty in small datasets [33]. Therefore, in small
datasets, it is reasonable for a model not to be de-
veloped at all. Additionally, internal validation pro-
cedures can quantify the calibration slope. At
internal validation, calibration-in-the-large is irrele-
vant since the average of predicted risks will match
the event rate. In contrast, calibration-in-the-large is
highly relevant at external validation, where we
often note a mismatch between the predicted and
observed risks.
When we find poorly calibrated predictions at val-
idation, algorithm updating should be considered to
provide more accurate predictions for new patients
from the validation setting [1, 20]. Updating of
regression-based algorithms may start with changing
the intercept to correct calibration-in-the-large [34].
Full refitting of the algorithm, as in the case study
below, will improve calibration if the validation sam-
ple is relatively large [35]. We present a detailed il-
lustration of updating of the ROMA model in
Additional file 1. Continuous updating strategies are
also gaining in popularity; such strategies dynamically
address shifts in the target population over time [36].
Published case study on the diagnosis of obstructive
coronary artery disease
Consider a logistic regression model to predict ob-
structive coronary artery disease (oCAD) in patients
with stable chest pain and without a medical history
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Fig. 2 (See legend on next page.)
Van Calster et al. BMC Medicine          (2019) 17:230 Page 5 of 7
of oCAD [37]. The model was developed on data
from 5677 patients recruited at 18 European and
American centers, of whom 31% had oCAD. The al-
gorithm was externally validated on data from 4888
patients in Innsbruck, Austria, of whom 44% had
oCAD [38]. The algorithm had an AUC of 0.69.
Calibration suggested a combination of overesti-
mated (intercept − 1.04) and overly extreme risk pre-
dictions (slope 0.63) (Fig. 2a). Calibration was
improved by refitting the model, i.e., by re-
estimating the predictor coefficients (Fig. 2b).
Conclusions
The key arguments of this paper are summarized in
Table 1. Poorly calibrated predictive algorithms can be
misleading, which may result in incorrect and potentially
harmful clinical decisions. Therefore, we need prespeci-
fied modeling strategies that are reasonable with respect
to the available sample size. When validating algorithms
it is imperative to evaluate calibration using appropriate
measures and visualizations – this helps us to under-
stand how the algorithm performs in a particular setting,
where predictions may go wrong, and whether the algo-
rithm can benefit from updating. Due to local healthcare
systems and referral patterns, population differences be-
tween centers and regions are expected; it is likely that
prediction models do not include all the predictors
needed to accommodate these differences. Together with
the phenomenon of population drifts, models ideally re-
quire continued monitoring in local settings in order to
maximize their benefit over time. This argument will be-
come even more vital with the growing popularity of
highly flexible algorithms. The ultimate aim is to
optimize the utility of predictive analytics for shared
decision-making and patient counseling.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-019-1466-7.
Additional file 1. Detailed illustration of the assessment of calibration
and model updating: the ROMA logistic regression model.
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Table 1 Summary points on calibration
Why calibration
matters
- Decisions are often based on risk, so predicted
risks should be reliable
- Poor calibration may make a prediction model
clinically useless or even harmful
Causes of poor
calibration
- Statistical overfitting and measurement error
- Heterogeneity in populations in terms of
patient characteristics, disease incidence or





- Perfect calibration, where predicted risks are
correct for every covariate pattern, is utopic;
we should not aim for that
- At model development, focus on nonlinear
effects and interaction terms only if a sufficiently
large sample size is available; low sample sizes
require simpler modeling strategies or that no
model is developed at all
- Avoid the Hosmer–Lemeshow test to assess
or prove calibration
- At internal validation, focus on the calibration
slope as a part of the assessment of statistical
overfitting
- At external validation, focus on the
calibration curve, intercept and slope
- Model updating should be considered in
case of poor calibration; re-estimating the
model entirely requires sufficient data
(See figure on previous page.)
Fig. 2 Calibration curves when validating a model for obstructive coronary artery disease before and after updating. a Calibration curve before
updating. b Calibration curve after updating by re-estimating the model coefficients. The flexible curve with pointwise confidence intervals (gray
area) was based on local regression (loess). At the bottom of the graphs, histograms of the predicted risks are shown for patients with (1) and
patients without (0) coronary artery disease. Figure adapted from Edlinger et al. [38], which was published under the Creative Commons
Attribution–Noncommercial (CC BY-NC 4.0) license
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